Luminon-Based Proteoform Analysis for Therapeutic Protein Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current LC-MS/MS and CE-MS/MS methods are limited in their ability to acquire tertiary and quaternary structural data, recognize chemical structure attributes (CSAs) operating in synchrony within a proteoform, and quantify the therapeutic potential of recombinant therapeutic proteins (RTPs), failing to assess the functional quality of RTPs through biological quality attributes (BQAs) that impact therapeutic performance.
Innovation Solution
The use of luminon mimics to directly appraise the therapeutic potential of RTPs by recognizing and binding to BQAs in a single proteoform, utilizing mobile affinity selection chromatography (MASC) platforms that mimic the in-vivo environment, enabling rapid assessment of RTPs through molecular recognition and fluorescence coding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If LC-MS/MS and CE-MS/MS methods are used for RTP quality management, then chemical structure attributes can be analyzed, but the ability to acquire tertiary and quaternary structural data and quantify therapeutic potential is limited
Solution Approach 1:
The patent introduces luminon molecules as intermediary probes that mediate between the RTP and the detection system. These luminons bind to specific BQAs on the RTP surface and transfer energy via FRET, enabling indirect detection of structural and functional attributes that direct MS methods cannot access. This intermediary approach allows acquisition of tertiary/quaternary structural data without requiring complex MS instrumentation modifications.
Solution Approach 2:
The patent replaces the mechanical/physical separation and detection approach of LC-MS/MS with a biochemical recognition approach using luminon probes. Instead of relying on mass-to-charge ratio separation, the system uses molecular recognition events followed by optical detection via FRET, substituting the mechanical separation mechanism with a biochemical sensing mechanism that provides direct structural and functional information.
2Reliability
If comprehensive quality assessment of RTPs is performed using traditional methods, then chemical attributes are measured, but therapeutic potential and biological functionality remain unquantified
Solution Approach 1:
The patent performs preliminary binding of luminon probes to RTPs before detection, allowing the system to pre-establish the recognition events that will report on BQAs. This preliminary action enables rapid readout of therapeutic potential without requiring time-consuming sequential analyses, as the luminons are already positioned to report on multiple BQAs simultaneously upon excitation.
Solution Approach 2:
The luminon probe system is designed to be universal, with different luminon variants that can recognize different BQAs on the same or different RTPs. A single platform can assess multiple aspects of therapeutic potential (binding affinity, stability, immunogenicity risk) using the same fundamental detection mechanism, eliminating the need for multiple specialized assays and reducing total analysis time.
3Productivity
If molecular recognition based luminon coding is used to appraise therapeutic potential, then rapid assessment is achieved, but the system requires new analytical platforms
Solution Approach 1:
The patent uses luminon molecules as simplified copies or proxies for the actual BQAs they recognize. Instead of directly measuring complex BQA interactions, the system measures the simpler optical properties of luminons that have been programmed to report on those interactions. This copying approach enables rapid assessment by measuring the optical state of the luminon probes rather than directly analyzing the complex RTP structures.
Solution Approach 2:
The patent exploits color/fluorescence changes of luminon probes as they transition between different conformational states upon binding to BQAs. The FRET-based detection measures changes in fluorescence intensity or wavelength that correspond to specific BQA recognition events. This optical readout provides rapid, real-time information on therapeutic potential without requiring complex mechanical or chemical analysis equipment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a rapid, high-affinity assessment of RTPs, identifying potential toxicity or immunogenicity threats and ensuring therapeutic functionality, offering a more definitive and efficient quality management system for RTPs.
Implementation Method 1
The TPA assay described herein functions like the idiomatic canary in a mine. It provides an early warning of a problem; the broad objective being to assess in minutes the probability that a recombinant therapeutic protein (RTP) has lost its therapeutic potential or is potentially harmful. That is achieved in-vitro according to the present disclosure by using a luminon mimic of the disease protein target to simulate the in-vivo disease environment.
Implementation Method 2
immediate, high affinity recognition of the disease protein mimic by the luminon signifies a high probability of a high TPA
Data Source
AI summary
A proteoformic analytical platform and method enables analysis of multiple function-related structural features in single recombinant therapeutic protein (RTP) proteoform, rather than in a family of proteoforms. The platform and method achieve rapid identification and quantification of biological quality attributes (BQAs) of the (RTP), and provides a therapeutic performance appraisal (TPA) that assesses the quality of RTP.